Fierce had a team of 6 on the ground to take the industry's temperature, and we found buyout buzz, optimistic startups, relieved venture capitalists and open-bar-hunting journos. There was even levity: Industry tweeters rallied around the #JPMpickuplines hashtag to get doubly entendrous (Get it? "Endpoints?").
Be sure to check out our expansive conference slideshow, and, in case you missed any of our coverage, here's a rundown of Fierce's trip through J.P. Morgan:
FierceMedicalDevices
> This time, 'cautious optimism' at the J.P. Morgan Healthcare Conference
> TAVR surgical tool company, pain management startup grab venture cash
> U.S., EU regulators to mull GE's Alzheimer's imaging agent
> For med tech startups, fundraising hinges on proving value
> T2 readies pivotal trial for Candida assay
> Medtronic's Ishrak promises more M&A, globalization
FierceBiotech
> Big Data has arrived in biotech. Now what?
> GlaxoSmithKline commits venture cash to new $250M biotech startup fund
> Payer risk outrivals regulatory jitters as biggest biotech hurdle
> Tufts: Billions wasted in pharma R&D despite new biz models
> Buyout buzz: Biopharma players staying focused on bolt-on deals
> Celgene chief Hugin wows J.P. Morgan with blockbuster plans for 2013
> Bob Langer biotech lands first big biopharma deal with Amgen
FiercePharma
> Novartis CEO shopping for bolt-on deals at $4B, tops
> Merck CEO up for diversity and deals, but one bite at a time
> AbbVie CFO sees no need for big acquisition
> Teva CEO says job cuts are small part of efficiency plans
-- Damian Garde (email | Twitter)